Maitake D-Fraction and MD-Fraction: What to Know

Maitake (Grifola frondosa)

68.8% response rate

In a clinical study of 36 cancer patients, MD-fraction from maitake produced tumor regression or symptom improvement in 68.8% of breast cancer patients and 58.3% of liver cancer patients.

Kodama et al., Alt Med Rev, 2002

1984

D-fraction first patented by Nanba lab, Japan (Mayell 2001)

TLR4

separate immune receptor pathway via maitake protein GFP (Tsao 2013)

0 effect

D-fraction had no blood pressure effect vs SX-fraction (Talpur 2002)

Kodama et al., Alt Med Rev, 2002

View as image ↗

In 2002, Noriko Kodama and colleagues at Kobe Pharmaceutical University tested MD-fraction from maitake mushroom in 36 cancer patients.^[1] The results: tumor regression or symptom improvement in 58.3% of liver cancer patients, 68.8% of breast cancer patients, and 62.5% of lung cancer patients. These were patients on standard cancer treatment — MD-fraction was tested as an add-on, not a replacement.

This trial is small. Thirty-six people, no placebo control, no blinding. But it remains one of the few clinical studies testing a specific maitake extract in actual cancer patients with measured outcomes. Understanding what MD-fraction is, how it relates to D-fraction, and why these two compounds are not the same as generic maitake powder matters for anyone trying to evaluate what the research means.

This article covers the origins and structural differences of D-fraction and MD-fraction, the two immune-focused extracts from maitake (Grifola frondosa), alongside the third compound — SX-fraction — that targets metabolism rather than immunity. The maitake mushroom overview covers the full species; this article goes deeper on the extracts.

What D-Fraction Is and Where It Came From

D-fraction is a protein-bound beta-glucan extracted from the fruiting body of maitake (Grifola frondosa). The "D" reflects its discovery context, not a systematic naming scheme. It was identified in the early 1980s by Dr. Hiroaki Nanba and colleagues at Kobe Pharmaceutical University in Japan. The Nanba laboratory patented D-fraction in Japan in 1984 — the first formal characterization of a specific maitake extract as a defined bioactive compound.^[5]

The compound is a polysaccharide: a long chain of glucose units. But not all glucose chains behave the same way in the immune system. What makes D-fraction structurally significant is its branching pattern — a beta-1,6 glucan backbone with beta-1,3 branches. This specific architecture allows D-fraction to bind strongly to Dectin-1 receptors on immune cells. Dectin-1 is the receptor that macrophages use to recognize fungal cell walls. When D-fraction binds it, macrophages activate, cytokines are released, and NK (natural killer) cells are recruited.

Generic beta-glucans from oats, barley, or poorly extracted mushroom supplements have different branching patterns and bind Dectin-1 less efficiently. D-fraction's branching geometry is part of why it produces stronger immune activation than simpler polysaccharides at equivalent doses. The detailed molecular mechanism is covered in Maitake Bioactive Compounds: D-Fraction, MD-Fraction, and Beta-Glucans.

D-fraction is also protein-bound — a protein component accounts for roughly 20-30% of the total molecular weight. This protein fraction is not just structural filler. It contributes to the immune signaling and affects how quickly the compound is broken down in the gut. The protein component of maitake extracts also includes a distinct protein — GFP — that activates an entirely separate immune pathway. More on that below.

MD-Fraction: Enhanced D-Fraction With Better Dendritic Cell Activity

MD-fraction is not a different compound from D-fraction. It is a more highly purified version of D-fraction, developed by the Nanba laboratory after the original D-fraction work was underway.^[5]

The key functional difference between D-fraction and MD-fraction is in dendritic cell activation. Dendritic cells are the scouts of the immune system — they identify foreign material, process it, and direct T cells and NK cells to respond. MD-fraction produces superior dendritic cell maturation compared to D-fraction, via the Dectin-1 pathway.^[1] This distinction matters for cancer research, where dendritic cell activity is considered central to the immune system's ability to recognize and respond to tumor cells.

In practical terms: D-fraction is the original; MD-fraction is the refined version with stronger dendritic cell activity. Most consumer maitake supplements labeled "D-fraction" may contain either or some combination of both, depending on the manufacturer's extraction and purification process. Supplement labels rarely specify which fraction is present at what purity.

Three Fractions, Three Different Targets

To understand D-fraction and MD-fraction, it helps to know what they are not.

Maitake contains at least three pharmacologically active fraction categories, each with a different molecular structure and a different primary target in the body. The research on different fractions going to different places — and doing different things — is one of the clearest examples in medicinal mushroom science of why "mushroom supplement" is too imprecise to mean anything.

D-fraction and MD-fraction are beta-glucan polysaccharides. Their primary targets are immune cells: macrophages, NK cells, T cells, and dendritic cells. Their main research applications are immune support and cancer adjuvant therapy. They act through the Dectin-1 receptor.

SX-fraction is an alpha-glucan glycoprotein with a molecular weight of approximately 20,000 daltons — much smaller than D-fraction. Its primary target is the metabolic system, not immunity. SX-fraction activates insulin receptors, reducing insulin resistance, and produces antihypertensive effects.^[4]

The evidence that these fractions have different targets is not theoretical. Talpur and colleagues tested different maitake fractions directly against each other for blood pressure effects in rats.^[7] SX-fraction significantly lowered systolic blood pressure. D-fraction had essentially no effect on blood pressure. The fractions are doing different things in the body — they are not interchangeable versions of the same mechanism.

Preuss and colleagues confirmed this pattern for glucose: SX-fraction significantly lowered fasting blood glucose and blood pressure in diabetic rats, while the immune-focused fractions did not replicate these metabolic effects.^[4]

When a maitake supplement label says "full spectrum extract" without specifying which fractions are present at what levels, it is not providing the information needed to predict which effect — if any — the product might produce.

The Clinical Evidence: What the Kodama Studies Found

The most-cited clinical data for D-fraction and MD-fraction comes from two studies by Kodama and colleagues, both conducted at Kobe Pharmaceutical University.

The first, published in 2002, tested MD-fraction in 36 cancer patients as an add-on to their standard treatment.^[1] Patients had liver, breast, lung, stomach, or colon cancer. The outcomes tracked were tumor regression and symptom improvement.

Response rates varied by cancer type:

• Liver cancer: 58.3% tumor regression or symptom improvement
• Breast cancer: 68.8%
• Lung cancer: 62.5%
• Stomach cancer: 11.1%
• Colon cancer: 10.0% (with Vitamin C co-administration: 40.0%)

The results were not uniform across cancer types. Gastric and colorectal cancer patients responded poorly. The researchers noted that MD-fraction's Dectin-1 signaling pathway may be less effective in gastrointestinal tumors with different immune microenvironments.

This trial has real limitations. Thirty-six patients is a small cohort. There was no placebo control group. Without blinding, observer bias and placebo effects cannot be ruled out. These caveats are not reasons to dismiss the study — they are reasons to hold it as hypothesis-generating data rather than definitive evidence. It tells you that MD-fraction is worth investigating in controlled trials; it does not tell you that it works at a pharmaceutical level of certainty.

The second Kodama study, published in 2003, took a narrower question: does D-fraction actually increase NK cell activity in cancer patients?^[2] The cohort data showed that oral D-fraction administration significantly increased NK cell activity in cancer patients — moving from a clinically relevant immunological measurement to a human clinical population, not just laboratory cells or animal models.

This is meaningful because it bridges the mechanistic evidence (D-fraction activates NK cells in laboratory conditions) and the clinical question (does it do the same thing in patients with actual cancer?). The answer from Kodama 2003 appears to be yes, with the usual caveats about cohort study design.

D-Fraction's Direct Anti-Cancer Effect: Beyond Immune Stimulation

A finding that receives little attention in maitake supplement discussions: D-fraction appears to kill cancer cells directly, without needing the immune system as an intermediary.

Soares and colleagues tested D-fraction on breast cancer cells in a laboratory setting and found that D-fraction induced apoptosis — programmed cell death — through activation of the BAK-1 gene.^[3] BAK-1 is a pro-apoptotic gene in the Bcl-2 family. When it is activated, the cell initiates its own destruction.

This is mechanistically distinct from D-fraction's immune-stimulating effects. Most discussions of D-fraction assume it works by boosting immune surveillance — training NK cells and macrophages to find and kill tumor cells. The Soares finding shows a second pathway: D-fraction may also directly trigger cell death programs inside cancer cells.

Both mechanisms were identified in laboratory conditions, not in patients. Cell culture studies cannot tell you what happens when D-fraction is swallowed, digested, and reaches target tissues at whatever concentration survives the digestive process. But the dual mechanism — immunostimulation plus direct cytotoxicity — distinguishes D-fraction from simpler immune supplements.

Maitake's Second Immune Pathway: The GFP Protein

D-fraction and MD-fraction work through the Dectin-1 receptor. But they are not the only immune-active components in maitake fruiting body.

Tsao and colleagues characterized a specific maitake protein they named GFP (Grifola frondosa protein).^[6] GFP is not a polysaccharide — it is a protein, structurally unrelated to D-fraction. It activates NK cells and induces dendritic cell maturation through a TLR4-dependent mechanism. TLR4 is a pattern-recognition receptor that normally recognizes bacterial lipopolysaccharide (a component of bacterial cell walls). GFP appears to trigger the same receptor.

The implication: maitake's immune effects come from at least two independent molecular mechanisms operating in parallel. D-fraction and MD-fraction act through Dectin-1. GFP acts through TLR4. When you take a whole maitake fruiting body extract, you are getting both pathways — not just the beta-glucan mechanism that most supplement discussions focus on.

This distinction matters for understanding why research on isolated D-fraction may not fully capture the immune activity of a quality whole-fruiting-body maitake product. It also means that the question "is this maitake product standardized for D-fraction?" is important but not the whole story. For deeper pharmacology detail, see The Pharmacology of Grifola frondosa: How Maitake Works.

Evaluating Maitake Supplements for D-Fraction and MD-Fraction

The D-fraction and MD-fraction research establishes what these compounds do when prepared at research quality. Most consumer maitake products are not prepared at research quality. The following factors determine whether a product is likely to contain meaningful levels of the fractions studied.

Source material: fruiting body. All of the D-fraction and MD-fraction research — including Kodama 2002, Kodama 2003, and Soares 2011 — used preparations derived from maitake fruiting body, not mycelium. Mycelium-based maitake products have a different compound profile. If a maitake supplement is labeled as mycelium extract, it was not produced the way the research preparations were.

Beta-glucan percentage. D-fraction and MD-fraction are beta-glucan compounds. A supplement standardized to a declared beta-glucan percentage is one that has at minimum tested for this compound class. Products that list only "maitake powder" without beta-glucan content have not verified that the fraction is present at any meaningful level.

Third-party testing. The 2017 mushroom supplement quality data showing widespread mislabeling and filler content applies to maitake products as to any other medicinal mushroom supplement. Third-party analysis for beta-glucan content (not just polysaccharide content, which is a weaker measure that can include starch) distinguishes verified products from unverified ones.

The "D-fraction" label. The term "D-fraction" is not regulated. Any manufacturer can use it. The original research preparations came from the Nanba laboratory under specific extraction conditions. Authentic D-fraction products should be traceable to a manufacturer that licenses or replicates the Nanba extraction methodology. This is not always disclosed on labels.

For broader guidance on evaluating mushroom supplement quality across species, see How to Choose a Mushroom Supplement: A Buyer's Guide. For the fruiting body vs mycelium quality comparison, see Fruiting Body vs. Mycelium: Which Makes a Better Supplement?.

What the Evidence Adds Up To

D-fraction and MD-fraction are the best-characterized immune compounds from any culinary mushroom. The evidence base is limited — the clinical trials are small, mostly uncontrolled, and predominantly from one research group at Kobe Pharmaceutical University. But the mechanistic consistency across different study types (NK cell activation in patients, direct apoptosis induction in cells, dendritic cell maturation via Dectin-1) points in a consistent direction.

The evidence that different fractions do different things — D/MD for immunity, SX for metabolism — is one of the most practically useful findings in maitake research. It means that an immune-focused application calls for a different product specification than a glucose or blood pressure application. "Maitake supplement" as a category is too broad to be useful without fraction information.

For the traditional medicine context and the historical validation story, see Maitake in Japanese Medicine: Traditional Uses and Modern Validation. For the cancer evidence in depth, see Maitake D-Fraction and Cancer: The Complete Research Review.

The Bottom Line

D-fraction and MD-fraction are protein-bound beta-glucan extracts from maitake fruiting body, first isolated and patented by the Nanba laboratory in Japan in the 1980s. They activate immunity primarily through Dectin-1 receptors, and a separate maitake protein (GFP) provides a second immune pathway via TLR4. Clinical data from 36 cancer patients shows response rates of 58-68% for MD-fraction as a cancer treatment add-on, with important caveats about study size and design. A key finding that distinguishes D-fraction research from simpler immune supplements: it also induces direct apoptosis in cancer cells via BAK-1 gene activation, independent of immune stimulation.

Frequently Asked Questions

What is the difference between D-fraction and MD-fraction maitake?

MD-fraction is a higher-purity version of D-fraction, developed after the original D-fraction research. Both are protein-bound beta-glucan compounds from maitake fruiting body that activate immune cells through Dectin-1 receptors, but MD-fraction produces superior dendritic cell maturation compared to D-fraction. Dendritic cells direct the immune response to tumor cells, which is why MD-fraction has been the focus of cancer-related research. D-fraction was patented in Japan in 1984; MD-fraction was developed as a refinement of that original compound.

Is maitake D-fraction FDA approved?

No. D-fraction is sold as a dietary supplement in the United States and is not FDA approved as a drug. The clinical research behind D-fraction was conducted primarily in Japan, mostly by the Nanba laboratory at Kobe Pharmaceutical University. That research has not been submitted through the FDA drug approval pathway. Maitake supplements are regulated under DSHEA (Dietary Supplement Health and Education Act) — they do not require clinical trial evidence for safety or efficacy before sale. The Kodama 2002 and Kodama 2003 studies provide clinical data on MD-fraction and D-fraction respectively, but these are not FDA-recognized trials.

How much maitake D-fraction should I take?

The Kodama 2002 MD-fraction cancer study did not publish the specific dose used. The Kodama 2003 NK cell study in cancer patients similarly does not specify a standardized dose in terms directly applicable to consumer supplements. Doses in maitake research have ranged from approximately 35 mg to over 100 mg of D-fraction extract per day, with total dried mushroom powder doses varying widely between products. There is no established clinical dosing range from controlled trials that translates directly to consumer supplement dosing.

What is the best maitake supplement D-fraction?

The research criteria for a high-quality D-fraction product are: (1) derived from maitake fruiting body, not mycelium, since all research preparations used fruiting body; (2) standardized to a declared beta-glucan percentage with third-party verification; (3) traceable to a manufacturer that licenses or replicates the Nanba extraction methodology. The term "D-fraction" is not regulated, so any maitake product can use it without verification. Products from manufacturers who publish beta-glucan content from independent laboratory testing provide more meaningful quality information than those relying on the label claim alone.

Sources & References

1. 1RTHM-00095·Kodama, Noriko et al. (2002). “Can maitake MD-fraction aid cancer patients?.” Alternative medicine review : a journal of clinical therapeutic.Study breakdown →PubMed →↩
2. 2RTHM-00112·Kodama, Noriko et al. (2003). “Effect of Maitake (Grifola frondosa) D-Fraction on the activation of NK cells in cancer patients..” Journal of medicinal food.Study breakdown →PubMed →↩
3. 3RTHM-00435·Soares, Raquel et al. (2011). “Maitake (D fraction) mushroom extract induces apoptosis in breast cancer cells by BAK-1 gene activation..” Journal of medicinal food.Study breakdown →PubMed →↩
4. 4RTHM-00262·Preuss, Harry G et al. (2012). “Fraction SX of maitake mushroom favorably influences blood glucose levels and blood pressure in streptozotocin-induced diabetic rats..” Journal of medicinal food.Study breakdown →PubMed →↩
5. 5RTHM-00080·Mayell, M (2001). “Maitake extracts and their therapeutic potential..” Alternative medicine review : a journal of clinical therapeutic.Study breakdown →PubMed →↩
6. 6RTHM-00558·Tsao, Yao-Wei et al. (2013). “Characterization of a novel maitake (Grifola frondosa) protein that activates natural killer and dendritic cells and enhances antitumor immunity in mice..” Journal of agricultural and food chemistry.Study breakdown →PubMed →↩
7. 7RTHM-00052·Talpur, Nadeem et al. (2002). “Effects of Maitake mushroom fractions on blood pressure of Zucker fatty rats..” Research communications in molecular pathology and pharmacology.Study breakdown →PubMed →↩